Eli Lilly is set to unveil crucial data from multiple late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The company plans to release results from five studies in patients with Type 2 diabetes and two trials in individuals with obesity in 2025. In phase two trials, overweight or obese patients taking 36 milligrams of the pill daily lost an average of 13.5% of their body weight after 36 weeks, compared to a 2.3% loss for those on placebo. For diabetes patients, expected weight loss is between 6% to 8%, with hemoglobin A1c levels improving by 1.8 to 2.1 points. Analysts predict orforglipron’s nausea rates to be below 25% and vomiting rates in the low double digits for diabetes patients, with slightly higher gastrointestinal side effects in obesity patients. The pill’s success could validate oral GLP-1 administration and impact the competitive landscape of the weight loss drug market, projected to reach over $150 billion annually by the early 2030s, with oral GLP-1s potentially contributing $50 billion.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
